Prostate cancer screening with prostate-specific antigen: A guide to the guidelines
Open Access
- 1 December 2016
- journal article
- review article
- Published by Elsevier in Prostate International
- Vol. 4 (4) , 125-129
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Screening for Prostate Cancer: Results of the Rotterdam Section of the European Randomized Study of Screening for Prostate CancerEuropean Urology, 2013
- Radical Prostatectomy versus Observation for Localized Prostate CancerNew England Journal of Medicine, 2012
- Prostate‐specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancerBJU International, 2012
- Mortality Results from a Randomized Prostate-Cancer Screening TrialNew England Journal of Medicine, 2009
- Why Are a High Overdiagnosis Probability and a Long Lead Time for Prostate Cancer Screening So Important?JNCI: Journal of the National Cancer Institute, 2009
- Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and ContextJNCI: Journal of the National Cancer Institute, 2009
- Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: Early resultsUrologic Oncology: Seminars and Original Investigations, 2006
- COMPARISON OF SCREEN DETECTED AND CLINICALLY DIAGNOSED PROSTATE CANCER IN THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER, SECTION ROTTERDAMJournal of Urology, 2005
- Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysisHealth Economics, 2004
- BENIGN AND MALIGNANT NEOPLASMS OF PROSTATEJournal of Urology, 2000